VTE (venous thromboembolism) is the third leading cause of death by cardiovascular disease. Standard treatment for acute (sudden onset) VTE's uses a combination of subcutaneous (injection under the skin) Low-Molecular-Weight-Heparin & oral vitamin K antagonists (drugs to keep a blood clot from getting worse) and carries significant bleeding risk. This treatment is difficult due to subcutaneous injections, drug interactions and laboratory testing. Direct Oral Anticoagulants (DOAC) are simpler to use and do not require laboratory testing. Rivoraxaban and Apixaban are both proven effective and safe anticoagulant drugs. However, because of limitations in research and not being able to directly compare them, it is difficult to be sure which is safest. Both are considered standard of care medications. Without knowing the differences in safety between each drug, we cannot be certain which DOAC has the best risk-to-benefit ratio.
The prevalence of obesity is rising worldwide, both in low- and high-income countries, including in people living with HIV (PLWH). Semaglutide is a drug whose effectiveness in achieving weight loss in PLWH and obesity is still unexplored. The aim of this study is to figure out the effectiveness and safety of semaglutide, in achieving greater weight loss compared to diet and exercise alone, in a group of PLWH and obesity. Additionally, this study aims to explore the effect of semaglutide on the immune function, markers of immune activation (that help our immune system respond to infections), viral reservoir (a safe hiding spot in the body for viruses to stay inactive or dormant), markers of glucose (blood sugar) and lipid (fatty compound) metabolism and gut microbiome (microorganisms that live in your digestive tract). The treatment stage of the trial will last for 28 weeks, with follow up until 40 weeks.
This is a prospective clinical trial (a study where individuals are followed over time) examining the immune response of participants receiving Modified Vaccinia Ankara (MVA), a vaccine for the prevention of monkeypox (Mpox) infection. Participants may receive MVA 0.1ml intradermally (a shallow injection) or MVA 0.5ml subcutaneously (a deeper injection) on one or two occasions as part of routine clinical care. Participants will attend 5 follow up visits over 48 weeks after their first dose of MVA. The main aim of this trial is to find out the rate of change of (durability), and factors associated with, MVA-specific antibodies (proteins that help remove infection) after 48 weeks post vaccination with MVA.
This study aims to determine if ziltivekimab can be used to treat people living with heart failure and inflammation in reducing the risk of cardiovascular death and heart failure events. Participants will receive either ziltivekimab or placebo (a pill with no active drug ingredient). The study drug will be given through monthly injections, using either a pre-filled syringe or a pen-injector. The trial is expected to last for up to 4 years. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires.
